Pacific Biosciences of California (PACB) : During the past 4 weeks, traders have been relatively bearish on Pacific Biosciences of California (PACB), hence the stock is down -8.4% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.48% relative to the S&P 500. The 4-week change in the price of the stock is -2.21% and the stock has fallen -0.87% in the past 1 week.
Pacific Biosciences of California (NASDAQ:PACB): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.88 and $7.84 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.08. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.95, notching a gain of 0.51% for the day. The total traded volume was 829,479 . The stock had closed at $7.91 on the previous day.
The stock has recorded a 20-day Moving Average of 3.62% and the 50-Day Moving Average is 7.95%. Pacific Biosciences of California, Inc. has dropped 25.84% during the last 3-month period . Year-to-Date the stock performance stands at -39.45%.
Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.